61 studies found for:    burzynski
Show Display Options
Rank Status Study
21 Unknown  Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
Condition: Small Intestine Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
22 Unknown  Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma
Condition: Sarcoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
23 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer
Conditions: Kidney Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
24 Withdrawn Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage III Prostate Cancer;   Stage IV Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Drug: bicalutamide;   Drug: flutamide;   Drug: leuprolide acetate;   Procedure: alternative product therapy;   Procedure: antiandrogen therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy;   Procedure: endocrine therapy;   Procedure: hormone therapy
25 Unknown  Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
26 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors
Condition: Sarcoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
27 Withdrawn Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Conditions: Merkel Cell Carcinoma;   Islet Cell Carcinoma;   Neuroendocrine Carcinoma;   Pituitary Tumor
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
28 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
29 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Conditions: Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
30 Unknown  Antineoplaston Therapy in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
31 Completed Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
32 Terminated Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
33 Withdrawn Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
34 Withdrawn Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
35 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory High-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
36 Unknown  Antineoplaston Therapy in Treating Patients With Refractory or Recurrent Intermediate-Grade Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
37 Unknown  Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
38 Unknown  Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
39 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
40 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years